In conclusion, monitoring intravenous UFH infusions with the anti ... and fewer laboratory tests and heparin dosage changes. Our results provide additional support for the growing sentiment ...

The most prevalent reasons for exclusion included heparin infusion for less than 24 hours and inadequate protocol compliance. Inadequate protocol compliance was the reason for exclusion in 13 of ...

Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...

APAC is a heparin proteoglycan mimetic with antiplatelet and anticoagulant ... APAC is intended for in-hospital use and can be administered either locally or by IV infusion. Johanna Asklin, General ...

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

Administered either locally or by IV infusion, APAC is meant for in-hospital ... “Our innovative approach, using a heparin proteoglycan mimetic with targeting ability and retention on the ...

Juvenile and adult male rats were implanted with intravenous catheters and tested ... saline solution (0.6 or 0.3 ml of 1000 U/ml heparin in 30 ml saline for P86, or P32 and P22 ...

During this period, each center prospectively applied one of three periprocedural protocols: (a) two centers administered aspirin (250 mg IV); (b) one center administered aspirin and heparin (bolus+24 ...

Intraoperative heparin was administered in six patients (42.9%), and five of these had a postoperative heparin infusion. A single intraoperative IV dose of the GPIIb/IIIa inhibitor, abciximab, was ...